@JSabari

Thoracic medical oncologist, Perlmutter Cancer Center NYU Langone Health. Tweets are my own and not medical advice

 New York, NY
nyulangone.org/doctors/1356638894/joshua-k-sabari
Joined November 2010
  • Tweets213
  • Following864
  • Followers2.1K
30Media
Joshua Sabari, MD retweeted
John P. Leonard, MD@JohnPLeonardMDMay 31
Lung cancer updates from @JSabari of @nyulangone @Perlmutter_CC new data #ASCO26 @Aiims1742 @nyugrossman
9
24
3,117
From emerging therapies to new clinical research, #ASCO2026 brings oncology experts to Chicago, May 29–June 2. Join us for presentations from @nyulangone physicians and researchers. Check out the full list of our presenters: bit.ly/4fdKFt2
5
2
15
2,357
Joshua Sabari, MD retweeted
PeerView
@PeerViewMay 19
Join Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, FCAHS, Pasi A. Jänne, MD, PhD, FASCO, and Joshua Sabari, MD (@JSabari), on 5/30 at 6:30 PM CDT during #ASCO26 for an #NSCLC #MedEd event. Produced with @LUNGevity ➡️ bit.ly/2026EGFRLung-T #Oncology
8
15
253
Joshua Sabari, MD retweeted
OncUpdates
@OncUpdatesMay 11
🚨@OncBrothers are moderating the 3rd Annual Upstate Cancer Symposium! ⭐️Full Day CME event bringing the latest in oncology to community practice! @PTarantinoMD @jainprantesh @rukitamehta @rutikamehtaMD @DrR_DUNNE #OncTwitter #MedTwitter Full details: oncupdates.com/article/oncol…
8
10
1,029
Joshua Sabari, MD retweeted
Anirban Maitra@Aiims1742Apr 16
First line oral targeted therapy for advanced non small cell lung cancer, including responses observed in dreaded brain metastatic disease (thanks to the chemistry behind Zongertinib crossing BBB). New study in @NEJM nejm.org/doi/full/10.1056/NE… @JSabari @Perlmutter_CC
2
14
1
74
5,911
Joshua Sabari, MD retweeted
Misty Dawn Shields
@drshieldsmdFeb 20
Replying to @IDEOlogyHealth
Permitting NGS results do not identify oncogenic drivers or co-mutations that would favor alternative approaches (i.e., non IO, TKI instead).
1
6
581
You are invited to learn about Lung Cancer Treatment Breakthroughs at @Perlmutter_CC @nyulangone Thursday December 11, 2025 6-7PM EST @StermanDaniel, Benjamin Cooper, Harvey Pass, Abraham Chachoua. i.nyulangone.org/vl6
4
1
6
1,287
5
622
FDA approval for lung cancer med Hernexeos fiercepharma.com/pharma/boeh… @Perlmutter_CC @nyulangone @EGFRResisters @Exon20Group

Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med Hernexeos

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer Ingelheim is entering the oncology market. | Zongertinib got an accelerated...

fiercepharma.com
1
2
20
1,414
Joshua Sabari, MD retweeted
Oncology Brothers
@OncBrothers8 Aug 2025
Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+: - 71% ORR w/ 14.1mos mDoR - mPFS 12.4% - ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash #OncTwitter #MedTwitter
OncUpdates
@OncUpdates11 Jul 2025
Missed out on AACR 2025? Check out the highlights from Beamion Lung-1! @sawyer_bawek highlights the 🔑 takeaways below! oncupdates.com/articles/beam… 🔹ORR 71% 🔹mPFS 12.4 months 🔹Intracranial ORR 41% 🔹Improved AE profile @OncBrothers @AACR #MedTwitter #FOAMed #LungCancer #NSCLC
3
25
3
59
22,225
Joshua Sabari, MD retweeted
Stephen V Liu, MD
@StephenVLiu8 Aug 2025
FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD. fda.gov/drugs/resources-info…

FDA grants accelerated approval to zongertinib for non-squamous NSCLC

On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinas

fda.gov
6
36
115
8,706
Proud to work here @nyulangone @Perlmutter_CC
1
2
15
664
Honored to be an Expert Judge Mentor for #EGFRSummit! Submit your abstracts by 8/8 to be part of the next class of @EGFRSummit Young Investigators! ➡️ ce.ceconcepts.com/EGFR2025CF… #EGFR #LCSM #MedTwitter #MedEd
2
13
955
Joshua Sabari, MD retweeted
Eric K. Singhi, MD@lungoncdoc25 Jun 2025
Discussing data hot off the press here at #HawaiiLung25. Dr. Joshua Sabari reviews the latest FDA approval of DatoDXd for our patients with EGFR+ mNSCLC.
1
2
16
2,276
Joshua Sabari, MD retweeted
CURE Today
@cure_today20 Jun 2025
Advancements Reshape Treatment for Non-Small Cell Lung Cancer @JSabari @Perlmutter_CC @jainprantesh @RoswellPark #LungCancer curetoday.com/view/advanceme…

Advancements Reshape Treatment for Non-Small Cell Lung Cancer | CURE

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.

curetoday.com
3
11
826
📣 HCPs 📣 Do you treat pts w/ rare alterations of #NSCLC? Medical Oncologist Dr @JSabari and Debra Montague (President of @LungCancerEu/founder of @UKALK1) share views on: ➡️The pt pathway ➡️#MedOnc vs Patient needs ➡️The support currently available Watch the video/listen on Spotify/Apple: cor2ed.com/lung-connect/prog… 🤝Endorsed by several Patient Advocacy Groups, inc. @WarOnCancer @BrafBombers @Exon20Group @metcrusaders @BiomarkerCo @LungCancerEu & ALK Positive Europe Supported by an Independent Educational Grant from Boehringer Ingelheim #MedEd #NSCLC #PrecisionMedicine 📷
1
2
452
Joshua Sabari, MD retweeted
PeerView
@PeerView22 May 2025
Join Joshua Sabari, MD (@JSabari), Jonathan W. Goldman, MD, Gilberto Lopes, MD, MBA, FASCO (@GlopesMd), Zosia Piotrowska, MD, MHS (@ZPiotrowskaMD) & @OncBrothers, on 5/31 at 6:30 PM CDT during #ASCO25 for an #NSCLC #MedEd event. Produced w/ @Lungevity. bit.ly/25TT-T
1
12
1
20
1,912
Getting excited for ASCO 2025! Join us Sat, May 31 at The Sheraton Grand Chicago Riverwalk in Chicago 6 Ballroom for #PrecisionMedicine in #NSCLC at #ASCO25! 6:30 PM CDT Reg & Dinner | 7 PM CDTSymposium. @PeerView @LUNGevity @OncBrothers ➡️ bit.ly/25TT-T

Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted...

See a new #NSCLC activity via @PeerView @glopesMD @OncBrothers #ASCO #MedEd

peerview.com
17
1
24
2,196
Real World Data on Overall Survival in EGFR mutant NSCLC treated with first line Osimertinib @Perlmutter_CC @nyulangone @JTOonline jto.org/article/S1556-0864(2…

Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study...

Patients with NSCLC harboring EGFR mutations (EGFRm) have high mortality. The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC. We used longitudinal...

jto.org
2
16
60
4,699
Excited to work with CURE as the new editor in chief! Thank you @DrDebuTripathy for your vision. CURE magazine provides cutting edge advancements for patients with cancer, families and caregivers.@Perlmutter_CC @MDAndersonNews @cure_today curetoday.com/view/discussin…

Discussing the Mission of CURE With Our Former and New Editors-In-Chief | CURE

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

curetoday.com
2
2
11
1,148
Load more